UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating an ...

Earnings Announcement - The company will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024 [1] - The senior management team will host a webcast and conference call to review the results beginning at 4:30 p m Eastern Time on the same day [1] - The conference call can be accessed via webcast or by dialing 877-407-6184 for U S investors and 201-389-0877 for international investors with Conference ID 13748866 [1] - A replay of the webcast will be available for approximately 30 days on the company's website at www mimedx com following the conclusion of the event [1] Company Overview - The company is a pioneer and leader in helping humans heal, with over a decade of experience in assisting clinicians with chronic and hard-to-heal wounds [2] - It is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare [2] - The company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life [2] Contact Information - For investor relations inquiries, contact Matt Notarianni at 470-304-7291 or mnotarianni@mimedx com [3]

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: "Her Face Was Unrecognizable After an Explosion. A Placenta Restored It." The author underscored the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the la ...

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professiona ...

Core Viewpoint - Ten former employees of MiMedx Group, Inc. have filed counterclaims against the company, alleging that MiMedx engaged in fraudulent practices to exploit Medicare and pressured employees to sell products without FDA approval [1][2]. Group 1: Allegations Against MiMedx - The counterclaims assert that MiMedx pressured healthcare providers to use medically unnecessary products on vulnerable patients, including wounded veterans and diabetics [2]. - Allegations include that MiMedx incentivized fraud against the U.S. government, particularly Medicare, through predatory sales practices [2]. - The claims reference a warning letter from the FDA regarding MiMedx's AXIOFILL product, indicating that the company misled its sales team about the product's marketability [2][3]. Group 2: Employee Experience and Company Response - Former employees claim they were compelled to sell a product that the FDA determined could not be marketed without prior approval, leading to their departure from the company [3]. - The counterclaims describe the original lawsuit from MiMedx as an intimidation tactic against employees who left due to the company's alleged misconduct [1].

Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga., Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company. Jake Heikkinen, a former MiMedx employee, states in the filing that he left the placental biologics company because of "MiMedx's schemes to bilk Medicare and othe ...

Product Launch - MiMedx Group Inc announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed for complex wound management in surgical settings [1] - HELIOGEN contains Type I and Type III collagen, mimicking the native composition of structural connective tissue, and is shelf-stable [1] Strategic Expansion - The launch of HELIOGEN represents a strategic initiative to expand the company's surgical footprint, following the successful introduction of two new surgical products in late 2022 [2] - HELIOGEN is the company's first xenograft option and 510(k) cleared product, complementing its existing placental-based solutions in the surgical market [2] Product Features - HELIOGEN is a bovine-derived collagen matrix product indicated for managing moderately to heavily exudating wounds and controlling minor bleeding [3] - The product supports wound healing by allowing cell adhesion and migration into the wound site, and is provided in particulate form to conform to various wound types [3] Company Overview - MiMedx is a pioneer in wound care, with over a decade of experience in helping clinicians manage chronic and hard-to-heal wounds [4] - The company focuses on providing a leading portfolio of products for wound care, burn, and surgical sectors, aiming to be the global leader in healing solutions through innovation [4]

Marks MIMEDX's first publication in the 5th most-cited journal in the world About MIMEDX Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process The study evaluated two configurations of PURION processed placental-based allografts for their ability to regulate fibrotic processes as modeled in a physiologically relevant in vitro system. Both dehydrated human amnion chorion membrane (DHACM) and ...

MARIETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced the publication of a peer reviewed study characterizing a potential mechanism by which placental-based allografts modulate the occurrence of scarring and fibrosis in surgical procedures. The article, "Human amniotic membrane modulates collagen production and deposition in vitro" represents the Company's first publication in Nature and can be accessed online here. About MIMEDX Marks ...